Pharmaceuticals

Oligonucleotide Therapy Market Outlook 2026–2030 driven by precision medicine advancements and strong R&D focus

March 23, 2026March 24, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Oligonucleotide Therapy Market In 2026 And What Value Is Projected For 2030?

The oligonucleotide therapy market has seen substantial growth in its size over recent years. It is projected to expand from $6.2 billion in 2025 to $6.91 billion in 2026, with a compound annual growth rate (CAGR) of 11.5%. The historical growth in this market can be attributed to increasing research and development in oligonucleotide synthesis, growing demand for targeted therapies, advancements in molecular biology techniques, a rise in chronic and genetic diseases, and the early adoption of antisense and aptamer technologies.

The oligonucleotide therapy market is projected to undergo rapid expansion over the next few years, with its valuation expected to reach $10.87 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.0%. This anticipated growth during the forecast period is attributed to factors such as the increasing scope of personalized medicine, the integration of artificial intelligence in drug discovery, the proliferation of precision medicine initiatives, the development of next-generation delivery platforms, and an uptick in partnerships between biotech and pharma companies. Prominent trends observed in this period include targeted gene regulation, RNA interference-based therapeutics, the evolution of personalized medicine, sophisticated drug delivery systems, and nucleic acid-based diagnostics.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3398&type=smp

What Major Drivers Are Influencing Demand In The Oligonucleotide Therapy Market?

The future expansion of the oligonucleotide therapy market is anticipated to be significantly propelled by government-led efforts in healthcare research and development. These government initiatives encompass distinct actions, programs, policies, or projects implemented by authorities at various levels—local, regional, national, or international—aimed at addressing specific issues, achieving set goals, or fostering positive societal advancements. Numerous governmental bodies are currently launching diverse healthcare programs to bolster various sectors, including oligonucleotide therapy. As an illustration, in April 2025, the American Medical Association, a US-based professional organization, reported that U.S. health spending rose by 7.5% to $4.9 trillion in 2023, amounting to $14,570 per capita, thereby exceeding the 4.6% increase observed in 2022. Consequently, governmental initiatives focused on healthcare research and development are acting as a key driver for the growth of the oligonucleotide therapy market.

What Are The Key Segments Of The Oligonucleotide Therapy Market?

The oligonucleotide therapy market covered in this report is segmented –

1) By Type: Antisense Oligonucleotide, Aptamer, Other Types

2) By Application: Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Other End-User

3) By End User: Hospitals, Research Institutes

Subsegments:

1) By Antisense Oligonucleotide: RNA-Targeted Antisense Oligonucleotides, DNA-Targeted Antisense Oligonucleotides, Chemically Modified Antisense Oligonucleotides

2) By Aptamer: DNA Aptamers, RNA Aptamers, Small Molecule Aptamers

3) By Other Types: siRNA (Small Interfering RNA), miRNA (Micro RNA), DNAzyme And Ribozymes, Synthetic Oligonucleotides For Gene Editing

What Key Trends Are Influencing The Development Of The Oligonucleotide Therapy Market?

Leading companies in the oligonucleotide therapy market are concentrating on developing advanced treatments, such as gene therapies, to address the fundamental cause of genetic diseases, enhance patient outcomes, and reduce the burden of long-term treatment. Gene therapies are sophisticated medical interventions designed to introduce a functional gene into a patient’s cells to compensate for a non-functional or mutated one. For example, in June 2023, Sarepta Therapeutics Inc., a US-based biotechnology company, obtained Food and Drug administration (FDA) approval for ELEVIDYS. This groundbreaking gene therapy is intended for ambulatory pediatric patients suffering from Duchenne muscular dystrophy (DMD). It is a single-dose treatment formulated to deliver a gene that codes for a shortened functional form of dystrophin to muscle cells, with the goal of halting or reversing the disease’s progression.

Who Are The Leading Companies Operating In The Oligonucleotide Therapy Market?

Major companies operating in the oligonucleotide therapy market are Pfizer Inc., GlaxoSmithKline plc, Gilead Sciences Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Avidity Biosciences Inc., Miragen Therapeutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies B.V., Evox Therapeutics Ltd., PepGen Ltd.

Read the full oligonucleotide therapy market report here:

https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Oligonucleotide Therapy Market?

North America was the largest region in the oligonucleotide therapy market in 2025. The regions covered in the oligonucleotide therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Oligonucleotide Therapy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3398&type=smp

Browse Through More Reports Similar to the Global Oligonucleotide Therapy Market 2026, By The Business Research Company

Oligonucleotides Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report

Oligonucleotide Synthesis Market Report 2026

https://www.thebusinessresearchcompany.com/report/oligonucleotide-synthesis-global-market-report

Nucleic Acid Based Gene Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795